Compare iShares MSCI Indonesia ETF (EIDO) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Hims and Hers Health Inc — how do they compare? iShares MSCI Indonesia ETF trades at $11.78 (market cap $409.22M), while Hims and Hers Health Inc trades at $28.41 (market cap $6.55B). The key difference: Hims and Hers Health Inc is far larger — about 16× iShares MSCI Indonesia ETF's market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 75 Days and Hims and Hers Health Inc for 21 Days on average.
| EIDO | HIMS | |
|---|---|---|
Market Cap | $409.22M | $6.55B |
Volume | 879,527 | 14,842,814 |
52-Week High | $19.22 | $62.76 |
52-Week Low | $10.80 | $14.52 |
Typical Hold Time | 75 Days | 21 Days |
Sector | — | Health |
Enterprise Value | — | $7.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.86, down 0.59% with bearish technical signals from moving averages. The ETF faces headwinds as foreign capital rotates away from Asian markets, with recent news highlighting Indonesia's failure to benefit from commodity gains despite attractive valuations. Trading volume declined 21% below average, indicating reduced investor interest.
The outlook remains cautious with technical weakness outweighing valuation appeal. Key risks include heavy financial sector exposure (44%) and limited EPS growth potential. Seasonal patterns historically favor July-August performance, but current market dynamics suggest continued pressure on Indonesian equities amid regional capital outflows.
Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.
The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
